US2016159887A1PendingUtilityA1
Immunotherapy and diagnosis of mucormycosis using coth
Assignee: LOS ANGELES BIOMED RES INSTPriority: Sep 15, 2011Filed: Feb 12, 2016Published: Jun 9, 2016
Est. expirySep 15, 2031(~5.2 yrs left)· nominal 20-yr term from priority
A61K 2039/505C07K 2317/76C07K 14/37G01N 33/56961C07K 2317/622C07K 2317/34G01N 2469/10C07K 2317/24A61P 31/10G01N 2333/37C07K 16/14
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provided Mucorales CotH antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The Mucorales CotH antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated anti-Mucorales CotH antibody, or binding fragment thereof, that specifically binds to a polypeptide expressed on the cell surface of a fungus of the order Mucorales, wherein the polypeptide comprises an amino acid sequence having at least 65% sequence identity to SEQ ID NO: 39 or SEQ ID NO: 40.
2 . The antibody of claim 1 , wherein the amino acid sequence has a least 80% sequence identity to SEQ ID NO: 39 or SEQ ID NO: 40.
3 . The antibody of claim 1 , wherein the amino acid sequence consists of SEQ ID NO: 39.
4 . The antibody of claim 1 , wherein the amino acid sequence consists of SEQ ID NO: 40.
5 . The antibody of claim 1 , wherein the antibody specifically binds to SEQ ID NO: 39.
6 . The antibody of claim 1 , wherein the antibody specifically binds to SEQ ID NO: 40.
7 . The antibody of claim 1 , wherein the fungus is a pathogenic fungus that can cause mucormycosis in a human.
8 . The antibody of claim 7 , wherein the pathogenic fungus belongs to a genus selected from the group consisting of Rhizopus, Rhizomucor, Lichtheimia, Mucor, Apophysomyces and Cunninghamella.
9 . The antibody of claim 8 , wherein the pathogenic fungus belongs to the genus Rhizopus.
10 . The antibody of claim 8 , wherein the pathogenic fungus belongs to the genus Lichtheimia or Mucor.
11 . The antibody of claim 8 , wherein the pathogenic fungus belongs to a species selected from Lechtheimia corymbifera, Cunninghamella bertholletia, Rhizopus microspores, Mucor racemosus, Mucor circinelloides, Rhizomucor variabilis, Apophysomyces elegans , and Apophysomyces trapeziformis.
12 . The antibody of claim 1 , wherein the antibody is a polyclonal antibody.
13 . The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
14 . The antibody of claim 13 , wherein the monoclonal antibody is a humanized antibody.
15 . The antibody of claim 13 , wherein the monoclonal antibody is a chimeric antibody
16 . The antibody of claim 1 , wherein the binding fragment is a single chain antibody.
17 . The antibody of claim 1 , wherein the antibody comprises a detectable marker.
18 . The antibody of claim 1 , wherein the antibody abrogates endocytosis of the fungus by a mammalian endothelial cell.
19 . An isolated anti-Mucorales CotH antibody, or binding fragment thereof, that specifically binds to a polypeptide expressed on the cell surface of a fungus of the genus Rhizopus , wherein the polypeptide comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 39 or SEQ ID NO: 40, and wherein the antibody abrogates endocytosis of the fungus by a mammalian endothelial cell.Join the waitlist — get patent alerts
Track US2016159887A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.